Brennan Daniel J.'s Form 4 filing
Boston Scientific Corp (BSX) · filed Feb 19, 2025
- Accession no.
- 0001225208-25-001969
- Filed
- Feb 19, 2025
- Trade date
- Feb 18-19, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $8.92M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brennan Daniel J.CIK 0001595612 | Officer (EVP and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | Common Stock | SSaleDisposed | −2,900 | $104.08F2 | −$301,832 | 247,248 | Direct | |
| Feb 18, 2025 | Common Stock | SSaleDisposed | −14,630 | $104.67F3 | −$1,531,322.1 | 232,618 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseAcquired | +18,533 | $24.55 | +$454,985.15 | 251,151 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseAcquired | +16,865 | $17.26 | +$291,089.9 | 268,016 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseAcquired | +15,642 | $27.09 | +$423,741.78 | 283,658 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseAcquired | +9,483 | $40.12 | +$380,457.96 | 293,141 | Direct | |
| Feb 19, 2025 | Common Stock | SSaleDisposed | −67,333 | $105.24F4 | −$7,086,124.92 | 225,808 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | Common Stock | MOption exerciseDisposed | −15,642 | $0.00 | $0 | 31,285 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseDisposed | −9,483 | $0.00 | $0 | 37,934 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseDisposed | −16,865 | $0.00 | $0 | 0 | Direct | |
| Feb 19, 2025 | Common Stock | MOption exerciseDisposed | −18,533 | $0.00 | $0 | 37,067 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.